Encouraging results, particularly in patients with low baseline cancer antigen 125 (CA-125), were observed in platinum-sensitive ovarian cancer when farletuzumab was administered alongside typical chemotherapy drugs [17,18]. The gene discussed is MUC16; the disease is ovarian carcinoma.